IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3348
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$487M
Kenneth T. Mills
REGENXBIO Inc. provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells to produce therapeutic proteins or antibodies that are intended to impact disease. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$RGNX REGENXBIO Inc. | 42 | 39 | 40 | 55 | - | - | -115.4% | -35.5% | 48.8% | -178.9% | -194.9% | 33.4% | 0.0% | 225.0x | $487M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
REGENXBIO Inc. (RGNX) receives a "Reduce" rating with a composite score of 41.5/100. It ranks #3348 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for RGNX.
View All RatingsROE proxy -115.4% (sector -1.9%)
GM 49% vs sector 44%, OM -179% vs sector 3%
Capital turnover N/A, R&D intensity 120.4%
Rev growth 33%, 10yr history
Interest coverage -4.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate REGENXBIO Inc. (RGNX) as a Reduce with a composite score of 41.5/100 at a current price of $8.05. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
REGENXBIO Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.5/100 places it at rank #3348 in our full universe.
No Moat
Very High
Poor
Fair Value
Gross margins of 49% signal strong pricing power.
Stable competitive position in a defensive sector.
Leverage of 225% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
REGENXBIO Inc. represents a reduce based on multi-factor quantitative performance.
REGENXBIO Inc. receives a Reduce rating from our analysis, with a composite score of 41.5/100 and 2 out of 5 stars, ranking #3348 out of 7,333 stocks. RGNX's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
RGNX's quality score of 39/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -115.4% (sector avg: -1.9%), gross margins of 48.8% (sector avg: 44.1%), net margins of -194.9% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 40/100, RGNX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 2.55x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
REGENXBIO Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 33.4% vs. a sector average of 6.7% and a return on assets of -35.5% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
RGNX demonstrates moderate momentum with a score of 55/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 33.4% year-over-year, while a beta of 1.73 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
RGNX's stability score of 31/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.73 and a debt-to-equity ratio of 225.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 56/100 for RGNX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 1.73), elevated leverage (D/E: 225.00x), small-cap liquidity risk. With a $487M market cap (small-cap), REGENXBIO Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
REGENXBIO Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3348 of 7,333 overall (54th percentile). Key comparisons include ROE of -115.4% trailing the -1.9% sector median and operating margins of -178.9% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While RGNX currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (25) would have the largest impact on the composite score.
ROE 5974% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 11% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 7226% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Robbins LLP has reminded investors of a class action lawsuit filed against REGENXBIO, Inc. (NASDAQ: RGNX) on behalf of those who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors about the viability of its drug candidate RGX-111, which later faced a clinical hold from the FDA due to a serious safety issue, leading to a significant drop in stock price. Investors can submit their papers to the court by April 14, 2026, to potentially serve as lead plaintiff.
Robbins LLP is informing investors of REGENXBIO, Inc. (NASDAQ: RGNX) about a class action lawsuit filed on behalf of shareholders who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors regarding the viability of its drug candidate RGX-111, which was later placed on clinical hold by the FDA due to safety concerns. Shareholders are encouraged to contact Robbins LLP to learn more about participating in the class action.
Rosen Law Firm has announced a class action lawsuit against REGENXBIO, Inc. (NASDAQ: RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors about the development and commercialization of its product candidate RGX-111, a gene therapy for Hurler syndrome, by disseminating false and misleading statements regarding its efficacy and safety. Stockholders with significant losses are urged to contact the firm by April 13, 2026, to learn about their rights.
H.C. Wainwright has lowered its price target for Regenxbio Inc. (NASDAQ:RGNX) to $32 from $34, while maintaining a Buy rating. This adjustment follows the FDA's rejection of the company's gene therapy RGX-121 for Hunter syndrome, citing concerns with study criteria. Despite the setback, the firm believes the delay does not impact Regenxbio's RGX-202 program, and the stock is considered undervalued by InvestingPro Fair Value metrics.
REGENXBIO Inc. (NASDAQ:RGNX) has received an average "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $30.38, and some analysts raising their targets to as high as $52.00. Institutional investors hold approximately 88.08% of the stock, with several hedge funds recently increasing their stakes. The company's shares are currently trading around $10.31, reflecting both volatility and the inherent risks of a clinical-stage biotechnology company.